CSL is approaching a 5-year low. Is this a buying opportunity?
Let's see if analysts think investors should be buying the dip with this quality stock. The post CSL is approaching a 5-year ...
Business Insider4y
The $24 billion plasma industry may be putting donors at risk
According to analysts at Fortune Business Insights, two-thirds of these centers are owned by one of three companies: CSL Plasma, Grifols, and BioLife. Even before the pandemic hit, global demand ...
Why is the CSL share price falling on Monday?
The CSL Ltd (ASX: CSL) share price is down 1.6% to $255.51 per share, while the S&P/ASX 200 Index (ASX: XJO) is trading in ...
Nature3y
A red blood cell disease meets a company with a plasma protein heritage
CSL Plasma is the largest collector of human blood ... Gene and cell therapy - Through the acquisition of Calimmune Inc., CSL Behring is now focused on the development of ex vivo haematopoietic ...
Are Sonic Healthcare or CSL shares a better buy?
Which of these healthcare giants is a better buy? The post Are Sonic Healthcare or CSL shares a better buy? appeared first on ...
pharmaphorum3y
Australia's CSL makes $11.7bn bid for Swiss pharma Vifor
If it goes through, the merger will allow CSL to diversify its business which is focused mainly on plasma-derived medicines sold by its CSL Behring unit and vaccines under the Seqirus arm ...
pharmaphorum4d
CSL, BrightInsight team up on digital health for rare diseases
CSL Behring is focused on the development and sale of plasma-served medicines such as immunoglobulins and recombinant drugs including clotting factors used to manage people with haemophilia and ...
Morningstar1mon
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body - ANDEMBRY reinforces CSL's decades-long commitment to delivering ...